According to a new report by UnivDatos Market Insights, The Latent TB Testing Market was valued at USD 1.4 Billion in 2023 and is expected to grow at a CAGR of 7.8% during the forecast period (2024-2032). Latent TB Testing determines individuals with asymptomatic Mycobacterium tuberculosis infection who are likely to develop overt TB. Screening tests include the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), which identify a body’s reaction to the bacteria. These tests are important in the prevention of TB epidemics among multiple risk groups such as the immunocompromised as well as the healthcare givers. This is mainly due to the increasing rates of tuberculosis across the world increasing the need to detect latent TB to prevent active TB. Also, improvements in diagnostic tools like IGRAs increase the effectiveness and utilization in high-risk groups. In addition, TB control campaigns supported by the government and compulsory screening norms also contribute to the growth of the market.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=68927

On November 25 2023, Revvity, a global company that leverages innovation in Diagnostics and Life Sciences announced the country launch of its T-SPOT.TB test for latent TB screening, at MICROCON in Lucknow.

In March 2022, PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.

Segments that transform the industry

·        Based on application, the market is segmented into household contacts (HHC) of tuberculosis (TB) patients, people living with HIV (PLHIV), and others. People living with HIV are expected to grow with a significant CAGR during the forecast period (2024-2032). The PLHIV segment is one of the primary consumers in the latent TB testing market because such patients have a higher risk of developing active TB and, therefore, require regular and accurate tests. The recent expansion of tuberculosis diagnostics in HIV care programs worldwide has boosted the need for gender-precise and accurate tests such as IGRAs. Companies adopt by developing partnerships with HIV clinics and NGOs to deliver specific test solutions and by providing affordable easy-to-scale testing solutions to this risky group.

According to the report, the impact of Latent TB Testing has been identified to be high for the Asia-Pacific area.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=68927

Browse Related Reports:

·        MENA Primary Care Physicians Market

·        Deep Vein Thrombosis Market

·        Chronic Obstructive Pulmonary Disease Market

·        Autism Spectrum Disorder Market

·        Travel Vaccine Market

Some of how this impact has been felt include:

Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to a high tuberculosis incidence rate, improved understanding of the disease, and national efforts to eliminate the disease. Adding to this, large-scale screening is being carried out in countries such as India and China with the help of international organizations. Examples include offering low-cost diagnostic solutions, forming alliances with government organizations, and increasing market coverage to areas that have limited access to the products. A shift from conventional TSTs to advanced IGRAs within the urban regions also supports the growth of the market.